Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

BACKGROUND: Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-induced side effects without obtaining any benefit. The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jandu, Haatisha, Aluzaite, Kristina, Fogh, Louise, Thrane, Sebastian Wingaard, Noer, Julie B., Proszek, Joanna, Do, Khoa Nguyen, Hansen, Stine Ninel, Damsgaard, Britt, Nielsen, Signe Lykke, Stougaard, Magnus, Knudsen, Birgitta R., Moreira, José, Hamerlik, Petra, Gajjar, Madhavsai, Smid, Marcel, Martens, John, Foekens, John, Pommier, Yves, Brünner, Nils, Schrohl, Anne-Sofie, Stenvang, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722663/
https://www.ncbi.nlm.nih.gov/pubmed/26801902
http://dx.doi.org/10.1186/s12885-016-2071-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722663/
https://www.ncbi.nlm.nih.gov/pubmed/26801902
http://dx.doi.org/10.1186/s12885-016-2071-1

Ejemplares similares